文献速递免疫规划传染病防控与疫情报告

美国成人中SARS-CoV-2感染史与mRNA COVID-19疫苗接种后严重全身不良事件的关联

Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults.
PubMed 文献 · Vaccine · 2022-11-01

该研究采用嵌套病例对照设计,利用v-safe监测数据,纳入3,862例病例和11,586例对照,评估有SARS-CoV-2感染史的成人接种mRNA COVID-19疫苗第1剂后0-7天内发生需急诊或住院的严重全身不良事件的风险。结果显示,有感染史者发生严重全身不良事件的比值比在Moderna组为2.4(95%CI: 1.89, 3.09),在Pfizer-BioNTech组为1.5(95%CI: 1.17, 2.02)。多数在第1剂后发生严重全身不良事件的参与者,在第2剂后未因症状需要任何医疗关注。

要点

  • 有SARS-CoV-2感染史的成人接种mRNA COVID-19疫苗第1剂后,发生严重全身不良事件的风险高于无感染史者。
  • Moderna组有感染史者发生严重全身不良事件的OR为2.4(95%CI: 1.89, 3.09),Pfizer-BioNTech组为1.5(95%CI: 1.17, 2.02)。
  • 多数在第1剂后发生严重全身不良事件的参与者,在第2剂后未因症状需要任何医疗关注。

核心结论

  • SARS-CoV-2感染史与mRNA COVID-19疫苗第1剂后严重全身不良事件显著相关,且效应因疫苗种类而异。
  • 多数在第1剂后发生严重全身不良事件的参与者,在第2剂后未因症状需要任何医疗关注。

研究设计与样本

  • 采用嵌套病例对照研究设计,使用v-safe监测数据。
  • 参与者为≥18岁、于2020年12月14日至2021年5月9日期间接种第1剂的成人。
  • 病例报告接种后0-7天内的严重全身不良事件;每个病例按年龄、接种日期和接种后天数频数匹配3名对照。
  • 随访调查收集SARS-CoV-2感染史;潜在病例应答率为38.6%,潜在对照应答率为56.8%。

主要发现

  • 多变量分析纳入3,862例病例和11,586例对照。
  • 有接种前SARS-CoV-2感染史者发生严重全身不良事件的OR为2.4(Moderna,mRNA-1273;95%CI: 1.89, 3.09),高于无感染史者。
  • 有接种前SARS-CoV-2感染史者发生严重全身不良事件的OR为1.5(Pfizer-BioNTech,BNT162b2;95%CI: 1.17, 2.02),高于无感染史者。
  • 病例和对照中,第2剂后0-7天内因症状需要任何医疗关注均不常见。

临床怎么用

  • 疫苗提供者可利用这些发现,为有接种前SARS-CoV-2感染史、在第1剂后发生严重全身不良事件并考虑不接种后续mRNA COVID-19疫苗剂次的病人提供咨询。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk of experiencing a systemic adverse event (AE) after mRNA coronavirus disease 2019 (COVID-19) vaccination may be greater among persons with a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; data on serious events are limited. We assessed if adults reporting systemic AEs resulting in emergency department visits or hospitalizations during days 0-7 after mRNA COVID-19 vaccine dose 1 were more likely to have a history of prior SARS-CoV-2 infection compared with persons who reported no or non-severe systemic AEs. METHODS: We conducted a nested case-control study using v-safe surveillance data. Participants were ≥ 18 years and received dose 1 during December 14, 2020─May 9, 2021. Cases reported severe systemic AEs 0-7 days after vaccination. Three controls were frequency matched per case by age, vaccination date, and days since vaccination. Follow-up surveys collected SARS-CoV-2 histories. RESULTS: Follow-up survey response rates were 38.6 % (potential cases) and 56.8 % (potential controls). In multivariable analyses including 3,862 case-patients and 11,586 controls, the odds of experiencing a severe systemic AE were 2.4 (Moderna, mRNA-1273; 95 % confidence interval [CI]: 1.89, 3.09) and 1.5 (Pfizer-BioNTech, BNT162b2; 95 % CI: 1.17, 2.02) times higher among participants with pre-vaccination SARS-CoV-2 histories compared with those without. Medical attention of any kind for symptoms during days 0-7 following dose 2 was not common among case-patients or controls. CONCLUSIONS: History of SARS-CoV-2 infection was significantly associated with severe systemic AEs following dose 1 of mRNA COVID-19 vaccine; the effect varied by vaccine received. Most participants who experienced severe systemic AEs following dose 1 did not require medical attention of any kind for symptoms following dose 2. Vaccine providers can use these findings to counsel patients who had pre-vaccination SARS-CoV-2 infection histories, experienced severe systemic AEs following dose 1, and are considering not receiving additional mRNA COVID-19 vaccine doses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tompkins LK, Baggs J, Myers TR, et al. Association between history of SARS-CoV-2 infection and severe systemic adverse events after mRNA COVID-19 vaccination among U.S. adults. Vaccine. 2022. PMID: 36372665. doi:10.1016/j.vaccine.2022.10.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。